Histological Outcome of Fuzheng Huayu plus Entecavir Combination Therapy in Chronic Hepatitis B Patients with Significant Liver Fibrosis
Open Access
- 21 July 2020
- journal article
- research article
- Published by Xia & He Publishing in Journal of Clinical and Translational Hepatology
- Vol. 8 (3), 1-8
- https://doi.org/10.14218/jcth.2020.00004
Abstract
Background and Aims: To evaluate the efficacy of Fuzheng Huayu (FZHY), a Chinese herbal formula, plus entecavir (ETV) in regression of liver fibrosis in chronic hepatitis B (CHB) patients with significant fibrosis/cirrhosis.Keywords
This publication has 26 references indexed in Scilit:
- Traditional Chinese medicine for treatment of liver diseases: progress, challenges and opportunitiesJournal of Integrative Medicine, 2014
- Traditional Chinese Medicine (TCM) for fibrotic liver disease: Hope and hypeJournal of Hepatology, 2014
- qFibrosis: A fully-quantitative innovative method incorporating histological features to facilitate accurate fibrosis scoring in animal model and chronic hepatitis B patientsJournal of Hepatology, 2014
- Hepatitis B-associated fibrosis and fibrosis/cirrhosis regression with nucleoside and nucleotide analogsExpert Review of Gastroenterology & Hepatology, 2012
- Liver cirrhosisBest Practice & Research Clinical Gastroenterology, 2011
- Significant histopathology in Chinese chronic hepatitis B patients with persistently high–normal alanine aminotransferaseJournal of Viral Hepatitis, 2010
- Liver biopsy: The best, not the gold standardJournal of Hepatology, 2009
- Grading and staging systems for inflammation and fibrosis in chronic liver diseasesJournal of Hepatology, 2007
- Entecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis BThe New England Journal of Medicine, 2006
- A Comparison of Entecavir and Lamivudine for HBeAg-Positive Chronic Hepatitis BThe New England Journal of Medicine, 2006